Trial Scorecards

September 2008
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p8
The article presents different trial scorecards in hematology and oncology. For the intraperitoneal cisplatin in gastric cancer, patients in arm B experienced better relapse-free survival and OS compared to patients in arm A. The scorecard for risedronate in breast cancer shows that women were given 35 milligrams of risedronate or placebo weekly for a year. The trial for the postoperative versus preoperative chemotherapy in esophageal cancer aimed to compare neoadjuvant and adjuvant treatment with cisplatin and 5-FU.


Related Articles

  • A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma. Eatock, M M; Anthony, D A; El-Abassi, M; Wilson, P; Paul, J; Smith, M; Soukop, M; Evans, T R J // British Journal of Cancer;6/15/2000, Vol. 82 Issue 12, p1925 

    The standard treatment for advanced gastro-oesophageal cancer in the UK is epirubicin, cisplatin and continuous infusion 5-fluoruracil by an indwelling central venous catheter (ECF), which has significant morbidity. Raltitrexed (tomudex), a specific inhibitor of thymidylate synthase with a long...

  • Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Polee, M.B.; Hop, W.C.J.; Kok, T.C.; Eskens, F.A.L.M.; van der Burg, M.E.L.; Splinter, T.A.W.; Siersema, P.D.; Tilanus, H.W.; Stoter, G.; van der Gaast, A. // British Journal of Cancer;12/1/2003, Vol. 89 Issue 11, p2045 

    The objective of this study was to identify prognostic factors for survival in patients with advanced oesophageal cancer, who are treated with cisplatin-based combination chemotherapy. We analysed the baseline characteristics of 350 patients who were treated in six consecutive prospective trials...

  • Successfully treated synchronous double malignancy of the breast and esophagus: a case report. Singh, Abhishek; Khare, Ishwar Chandra; Dixit, Awadhesh Kumar; Pandey, Kailash Chandra; Mittal, Deepak Kumar; Singh, Parul // Journal of Medical Case Reports;2010, Vol. 4 Issue 1, p1 

    Introduction: The incidence of multiple primary cancers is reported to be between 0.3% and 4.3%. The second primary lesion is identified either simultaneously with the primary lesion (synchronous) or after a period of time (metachronous). Few cases of metastasis of breast carcinoma to the...

  • Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer. Faruk Tas; Nese Guney; Duygu Derin; Hakan Camlica; Adnan Aydiner; Erkan Topuz // Investigational New Drugs;Aug2008, Vol. 26 Issue 4, p363 

    Summary  Gemcitabine and cisplatin are the active agents in metastatic breast cancer pretreated with anthracycline and/or taxane as a second line treatment. The present study was designed to assess the efficacy and safety of this regimen given biweekly schedule in these patients....

  • Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Crosby, T.D.L.; Brewster, A.E.; Borley, A.; Perschky, L.; Kehagioglou, P.; Court, J.; Maughan, T.S. // British Journal of Cancer;1/12/2004, Vol. 90 Issue 1, p70 

    We performed a retrospective study of 90 consecutive cases with inoperable carcinoma of the oesophagus treated with definitive chemoradiation at a single cancer centre between 1995 and 2002. For the last 4 years, 73 patients have received therapy according to an agreed protocol. This...

  • Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma. Ma, G.; Kawamura, K.; Li, Q.; Okamoto, S.; Suzuki, N.; Kobayashi, H.; Liang, M.; Tada, Y.; Tatsumi, K.; Hiroshima, K.; Shimada, H.; Tagawa, M. // Cancer Gene Therapy;Nov2010, Vol. 17 Issue 11, p803 

    We examined possible combinatory antitumor effects of replication-competent type 5 adenoviruses (Ad) lacking E1B-55kDa molecules (Ad-delE1B55) and chemotherapeutic agents in nine human esophageal carcinoma cells. Ad-delE1B55 produced cytotoxic effects on all the carcinoma cells and the...

  • The efficacy of preoperative cisplatin and 5-fluorouracil combination in patients with stage III squamous cell carcinoma of the esophagus. Han, Serdar; Yalçin, Bülent; Akbulut, Hakan; Ökten, Ilker // Turkish Journal of Cancer;Jan2005, Vol. 35 Issue 1, p26 

    We aimed to assess the efficacy of neoadjuvant cisplatin and 5-fluorouracil (CF) combination chemotherapy in patients with potentially resectable squamous cell carcinoma of the esophagus. Thirteen consecutive patients with clinically stage III esophagus carcinoma were included in this study....

  • Docetaxel and Irinotecan Combination Chemotherapy in Advanced Esophageal Cancer. Shanbhag, Satish; Burtness, Barbara // European Journal of Clinical & Medical Oncology;2011, Vol. 3 Issue 1, p1 

    Metastatic esophageal cancer is incurable with 5-year survival rates of under 5% using currently available therapeutic strategies. Palliative chemotherapy with cisplatin- and 5-fluorouracil (5FU)-based regimens remains the standard of care for patients with recurrent unresectable or metastatic...

  • Cisplatin.  // Reactions Weekly;1/9/2010 Part 1 of 2, Issue 1283, p31 

    The article presents the case of a 55-year-old man who developed sodium-wasting nephropathy while undergoing cisplatin-based chemotherapy for oesophageal cancer. The patient, who had a history of hypertension and diabetes, presented with lower levels of sodium and magnesium. Cisplatin will be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics